Practical Dermatology

Adding tofacitinib to systemic glucocorticoid therapy was associated with reduced glucocorticoid exposure and faster clinical improvement among patients with drug reaction with eosinophilia and systemic symptoms (DRESS), according to a study published online in the Journal of the American Academy of Dermatology. Investigators retrospectively evaluated patients with DRESS treated between January 2018 and June 2025, comparing systemic glucocorticoids alone with glucocorticoids plus tofacitinib.

A US expert consensus provides a standardized treatment framework for adults with severe alopecia areata (AA), placing oral Janus kinase (JAK) inhibitors at the center of long-term disease management. "This joint NAAF and AHRS Delphi consensus statement introduces the, what is to our knowledge, first standardized treatment recommendations for adults with severe AA in the US," the authors wrote in the paper, published in JAMA Dermatology.

Cardamonin demonstrated antifibrotic activity in human keloid fibroblasts by suppressing transforming growth factor β1 (TGF-β1)/Smad signaling, according to new in vitro research in the Journal of Drugs in Dermatology. Investigators treated a human keloid fibroblast cell line (KEL FIB) with increasing concentrations of cardamonin, assessing proliferation, clonogenic growth, apoptosis, migration, and invasion using CCK-8, colony formation, flow cytometry, wound-healing, and Transwell assays.

Botulinum toxin A (BTX-A) may offer dermatologists a way to address the functional, therapeutic, and aesthetic manifestations of facial paralysis within a single treatment framework, a recent review suggested.d The authors conducted a narrative review of PubMed-indexed literature examining aesthetic and therapeutic applications of BTX-A in facial paralysis and focused on 3 domains: facial asymmetry, functional impairment, and neuromuscular dysregulation.

Interest in facial skincare is growing among children and adolescents, new findings suggest. Researchers evaluated a 3-product regimen consisting of a hydrating cream cleanser, hydrating moisturizer, and daily mineral SPF 40 through pediatric safety-in-use studies, comedogenic and acnegenic assessments, and an adult Human Repeat Insult Patch Test. A separate cross-sectional survey examined skincare behaviors and attitudes among participants aged 8 to 17, 18 to 29, and 30 to 45 years.

A post hoc analysis of SELECT-PsA 2 found sustained responses with upadacitinib 15 mg once daily through 152 weeks among patients with psoriatic arthritis (PsA) previously exposed to 1 tumor necrosis factor inhibitor (TNFi). Published in RMD Open, the analysis included 195 patients with exposure to 1 prior TNFi. Investigators evaluated long-term efficacy and safety as well as whether duration of previous TNFi exposure, early pain response, and anatomic location of psoriasis affected outcomes.

The National Eczema Association (NEA) has expanded its Seal of Acceptance program to include color cosmetics, opening the program to makeup products for the first time since the Seal was established in 2008. The initial expansion covers base makeup products, including foundation, concealer, and primer, with additional cosmetic categories expected to follow.

PCA SKIN has launched Acne Control Prebiotic Gel Cleanser, a new daily cleanser formulated to address acne while supporting the skin barrier and microbiome, according to information provided by the company. The cleanser, launched September 1, combines 2% salicylic acid with 1% azelaic acid and 1% niacinamide. PCA SKIN states that salicylic acid exfoliates dead skin cells and helps clear pore-clogging debris, while azelaic acid is included to address visible redness and post-blemish marks.

Hidradenitis suppurativa (HS) carries a significant acute-care burden, but outpatient dermatology follow-up may be associated with fewer hospital readmissions, according to a study published in Archives of Dermatological Research. Researchers examined medical records from Henry Ford Health System to characterize emergency department visits and inpatient hospitalizations among adults with HS and assess the relationship between dermatology care and readmission.

Researchers have developed a fast-dissolving microneedle platform designed to address oxidative stress, inflammation, melanocyte loss, and depigmentation in vitiligo, according to a preclinical study published in Marine Life Science & Technology. The experimental C/D/E@MN platform combined cuttlefish ink nanoparticles (CINPs) for melanin supplementation, dipotassium glycyrrhizinate (DPG) to regulate inflammation, and skin-derived exosomes (EXO) intended to promote melanocyte proliferation.